APP and Alzheimer disease: Our recent studies on APPswe/PS1ΔE9 (APP/PS1) transgenic mice have demonstrated that HE‐My and its constituents, particularly HE‐A and HE‐S, can modulate glial activity, leading to favorable alterations in AD pathology [27, 28].